SIG 005
Alternative Names: SIG-005 - Sigilon TherapeuticsLatest Information Update: 18 Aug 2023
At a glance
- Originator Sigilon Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mucopolysaccharidosis I
Most Recent Events
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 05 May 2023 The US FDA withdraws Orphan Drug status for Mucopolysaccharidosis I in the US, prior to May 2023
- 31 Jan 2023 Discontinued - Preclinical for Mucopolysaccharidosis I in USA (Parenteral) before January 2023 (Sigilon Therapeutics Pipeline, January 2023)